• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤细胞增强了因子Xa催化的凝血酶原向凝血酶的转化。

Tumor cells augment the factor Xa-catalyzed conversion of prothrombin to thrombin.

作者信息

Sakai T, Noguchi M, Kisiel W

机构信息

Department of Pathology, University of New Mexico School of Medicine, Albuquerque.

出版信息

Haemostasis. 1990;20(3):125-35. doi: 10.1159/000216119.

DOI:10.1159/000216119
PMID:2387553
Abstract

Activation of blood coagulation and local fibrin deposition may contribute to tumor metastasis. We have examined the ability of four human tumor cell lines (COLO 205, HepG2, J82 and CAPAN-2) to augment the conversion of prothrombin to thrombin by factor Xa and calcium in the presence and absence of exogenous factor Va. Using a chromogenic substrate assay to assess thrombin formation, we observed that all the above cell lines accelerated prothrombin activation in the absence of exogenous factor Va. The order of effectiveness was COLO 205 greater than HepG2 greater than J82 greater than CAPAN-2. In the absence of cells, no detectable thrombin formation occurred. Pretreatment of COLO 205 and HepG2 cells with anti-human factor V IgG inhibited prothrombin activation in a dose-dependent manner, but was without effect in J82 and CAPAN-2 incubation mixtures. Factor V coagulant activity was observed in COLO 205 and HepG2 cells as well as their culture media, but was not detected in J82 and CAPAN-2 cells or their culture media. Biosynthetic labeling and immunoprecipitation studies revealed that COLO 205 and HepG2 cells constitutively synthesized factor V or a factor-V-like molecule that comigrated with human factor V/Va on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. All four tumor cell lines exhibited saturation binding of exogenous human factor Va resulting in a dose-dependent enhancement of their ability to augment prothrombin activation. Our results indicate that these tumor cells can readily assemble a functional cell surface prothrombinase complex that may be important in fibrin deposition associated with the growth and metastatic progression of these, and perhaps, other tumors.

摘要

血液凝固的激活和局部纤维蛋白沉积可能有助于肿瘤转移。我们检测了四种人类肿瘤细胞系(COLO 205、HepG2、J82和CAPAN - 2)在有和没有外源性因子Va的情况下,增强因子Xa和钙将凝血酶原转化为凝血酶的能力。使用发色底物分析法评估凝血酶的形成,我们观察到在没有外源性因子Va的情况下,上述所有细胞系都加速了凝血酶原的激活。有效性顺序为COLO 205大于HepG2大于J82大于CAPAN - 2。在没有细胞的情况下,未发生可检测到的凝血酶形成。用抗人因子V IgG预处理COLO 205和HepG2细胞以剂量依赖性方式抑制凝血酶原激活,但对J82和CAPAN - 2孵育混合物没有影响。在COLO 205和HepG2细胞及其培养基中观察到因子V促凝活性,但在J82和CAPAN - 2细胞及其培养基中未检测到。生物合成标记和免疫沉淀研究表明,COLO 205和HepG2细胞组成性地合成因子V或一种在十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳上与人因子V/Va共迁移的类因子V分子。所有四种肿瘤细胞系对外源性人因子Va均表现出饱和结合,导致其增强凝血酶原激活能力的剂量依赖性增强。我们的结果表明,这些肿瘤细胞可以很容易地组装一个功能性细胞表面凝血酶原酶复合物,这可能在与这些肿瘤以及或许其他肿瘤的生长和转移进展相关的纤维蛋白沉积中起重要作用。

相似文献

1
Tumor cells augment the factor Xa-catalyzed conversion of prothrombin to thrombin.肿瘤细胞增强了因子Xa催化的凝血酶原向凝血酶的转化。
Haemostasis. 1990;20(3):125-35. doi: 10.1159/000216119.
2
Binding of human factors X and Xa to HepG2 and J82 human tumor cell lines. Evidence that factor Xa binds to tumor cells independent of factor Va.
J Biol Chem. 1990 Jun 5;265(16):9105-13.
3
Bothrojaracin, a proexosite I ligand, inhibits factor Va-accelerated prothrombin activation.Bothrojaracin,一种外显子I配体,可抑制因子Va加速的凝血酶原激活。
Thromb Haemost. 2002 Feb;87(2):288-93.
4
Tumor cell generation of thrombin via functional prothrombinase assembly.肿瘤细胞通过功能性凝血酶原酶组装产生凝血酶。
Cancer Res. 1985 Nov;45(11 Pt 1):5521-5.
5
Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism.人凝血酶原酶对人凝血酶原的激活。因子Va对反应机制的影响。
J Biol Chem. 1987 Mar 5;262(7):3291-9.
6
Fibroblasts, glial, and neuronal cells are involved in extravascular prothrombin activation.成纤维细胞、神经胶质细胞和神经元细胞参与血管外凝血酶原激活。
J Biochem. 1999 Oct;126(4):655-61. doi: 10.1093/oxfordjournals.jbchem.a022499.
7
Inactivation of factor Va by activated protein C on selected human tumor cell lines.活化蛋白C对选定人类肿瘤细胞系中因子Va的灭活作用。
Haemostasis. 1992;22(4):165-72. doi: 10.1159/000216315.
8
The factor V activation paradox.因子V激活悖论。
J Biol Chem. 2004 May 7;279(19):19580-91. doi: 10.1074/jbc.M400727200. Epub 2004 Feb 24.
9
The interaction of fragment 1 of prothrombin with the membrane surface is a prerequisite for optimum expression of factor Va cofactor activity within prothrombinase.凝血酶原片段1与膜表面的相互作用是凝血酶原酶中因子Va辅因子活性最佳表达的先决条件。
Thromb Haemost. 2008 Mar;99(3):511-22.
10
The second kringle domain of prothrombin promotes factor Va-mediated prothrombin activation by prothrombinase.凝血酶原的第二个kringle结构域可促进凝血酶原酶介导的因子Va介导的凝血酶原激活。
J Biol Chem. 1995 Mar 3;270(9):4551-7. doi: 10.1074/jbc.270.9.4551.

引用本文的文献

1
Mandatory role of proteinase-activated receptor 1 in experimental bladder inflammation.蛋白酶激活受体1在实验性膀胱炎症中的关键作用。
BMC Physiol. 2007 Mar 30;7:4. doi: 10.1186/1472-6793-7-4.
2
Non-tissue factor procoagulants in cancer cells.癌细胞中的非组织因子促凝剂。
Cancer Metastasis Rev. 1992 Nov;11(3-4):267-82. doi: 10.1007/BF01307182.
3
Tissue factor as a tumor procoagulant.组织因子作为一种肿瘤促凝剂。
Cancer Metastasis Rev. 1992 Nov;11(3-4):249-66. doi: 10.1007/BF01307181.